NANOBIOTIX Provides First Quarter Operational and Financial Update

On-track to activate first US clinical trial sites in on-going pivotal phase III global registration study, NANORAY-312, in locally advanced head and neck squamous cell carcinoma (LA-HNSCC) in Q3 2022 Received preliminary feedback from FDA informing development of pivotal Phase III protocol for NBTXR3 in combination with anti-PD-1 therapy, protocol submission planned in Q1 2023 … [Read more…]

DermTech Presents New Research Differentiating Atopic Dermatitis and Psoriasis at the Society for Investigative Dermatology’s Annual Meeting

LA JOLLA, Calif.–(BUSINESS WIRE)–DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today its presentation at the Society for Investigative Dermatology’s (SID) annual meeting, held from May 18-21, 2022 in Portland, OR. Michael Howell, Ph.D., chief scientific officer at DermTech, presented new research … [Read more…]

Labcorp Launches New Test for People With Skin Cancer

New Assay for Patient Care and Use in Clinical Trials Could Lead to Expanded Treatment Options for Melanoma BURLINGTON, N.C.–(BUSINESS WIRE)–Finding treatment options for skin cancer may become easier with the launch of a new test by Labcorp (NYSE: LH), a leading global life sciences company. The new test measures Lymphocyte-activation gene 3 (LAG-3) expression … [Read more…]

Neurogene Announces New Development Program in Rett Syndrome Utilizing Novel EXACT Technology Platform

Promising preclinical data for NGN-401 presented at 25th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) demonstrate significant survival benefit and reduced disease burden in Rett syndrome mouse model Results show Neurogene’s EXACT gene therapy regulates MECP2 gene expression to target levels, avoiding overexpression related toxicity EXACT platform holds potential to … [Read more…]

Adicet Bio to Present at Upcoming Investor Conferences

MENLO PARK, Calif. & BOSTON–(BUSINESS WIRE)–Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing first-in-class allogeneic gamma delta chimeric antigen receptor (CAR) T cell therapies for cancer, today announced that company management will participate in two upcoming investor conferences in May and June. Details of the events are as follows: H.C. … [Read more…]

ReCode Therapeutics Presents New Preclinical Data from mRNA-based Program for Cystic Fibrosis at the ATS 2022 International Conference

Study confirms the ability of ReCode’s Selective Organ Targeting (SORT) lipid nanoparticle (LNP) platform to deliver optimized, functional CFTR mRNA as an aerosol directly to specific cell targets Results show consistent rescue of CFTR function across multiple cystic fibrosis patient genotypes, including genotypes that do not respond to approved CFTR modulator treatments MENLO PARK, Calif. … [Read more…]

Lionheart Acquisition Corporation II Shareholders Approve Previously Announced Business Combination with MSP Recovery

LCAP shareholders have approved the previously announced business combination at the Special Meeting held on May 18, 2022 Transaction Expected to Close May 20, 2022 CORAL GABLES, Fla.–(BUSINESS WIRE)–Lionheart Acquisition Corporation II (Nasdaq: LCAPU, LCAP, LCAPW, “Lionheart” or “LCAP”), a publicly traded special purpose acquisition company, today announced that shareholders of record as of April … [Read more…]

neuro42 Licenses Robot from Johns Hopkins University

SAN FRANCISCO–(BUSINESS WIRE)–neuro42, Inc. (“neuro42” or the “Company”), a medical imaging, robotics, and AI technology company, today announced an exclusive licensing agreement with Johns Hopkins University (“Johns Hopkins”) for their MR compatible robot for head, neck and spine applications, with additional non-exclusive licenses for related technologies and patents. Developed by Dr. Dan Stoianovici, director of … [Read more…]

Cerebral President and CMO David Mou, MD, Named Chief Executive Officer as CEO Kyle Robertson Leaves Position

Chief Operating Officer Jessica Muse Assumes President Role for Company, Clinical Advisor Thomas Insel agrees to join Board SAN FRANCISCO–(BUSINESS WIRE)–#Cerebral–David Mou, MD MBA, the company’s President and Chief Medical Officer, has been named as Cerebral’s Chief Executive Officer. Cofounder Kyle Robertson leaves his position as CEO, effective immediately. “We thank Kyle for his service. … [Read more…]

CHD Files Comments with FCC Urging Accommodation of Millions of People Sickened by Wireless Radiation

WASHINGTON–(BUSINESS WIRE)–On May 16, Children’s Health Defense (CHD) and 50 other safe tech and health advocacy non-profits filed legal comments with the Federal Communications Commission (FCC) in response to the FCC’s request for comment on how to “prevent and eliminate digital discrimination.” The proceeding was required by the Infrastructure Investment and Jobs Act (“Infrastructure Act”) … [Read more…]